NuuVim review
Injection and oral cost the same on each molecule, which is unusual. The seller states no membership and one price at any dose.
The verdict
NuuVim's standard rates are $133 a month for compounded semaglutide and $199.67 for compounded tirzepatide. Each is billed as a three-month plan. The figure does not change between the injection and the oral. Brand Ozempic is listed separately at $1,498 a month.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 sellers by price
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Dose pricing
- Flat across doses
- Injection
- From $133/mo
- Oral
- From $133/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
NuuVim sells both molecules in two forms each. That is four compounded lines. A branded line sits beside them at a cash price.
Who writes the prescription, and what do they see?
A prescription is written before anything ships, and the pages describe the plan rather than the clinician. Who writes it is not stated.
The pricing is the clear part. Four lines, two numbers, and the form does not move either one. The seller also prints a table comparing itself with unnamed rivals at $279 to $325.
What happens when the dose goes up?
NuuVim states the price is the same at any dose. That claim is printed in its own comparison table, beside a claim of no membership fee. Both are the seller's words rather than anything measured here, and both are worth confirming in writing before a first charge.
What the price includes
Semaglutide is $399 per three months, or $133 a month. Tirzepatide is $599, or $199.67 a month. Six months is $798 and $1,198. New GLP-1 users are shown a lower introductory tab. The standard rate is what a returning patient pays.
What it claims, and what it cites
The four cheaper lines are compounded rather than manufactured. A pharmacy prepares them, the FDA does not review a compounded preparation before it is dispensed, and no pharmacy is named. The Ozempic line is the branded product at a cash price.
Where it holds up, and where it does not
- Strength: The same figure whether injected or taken orally
- Strength: Four compounded lines all priced openly
- Strength: A branded option priced beside them rather than hidden
- Limitation: Billing runs in three-month blocks
- Limitation: The intro tab is for new GLP-1 users only
- Limitation: The no-membership and any-dose claims are unverified
- Limitation: No pharmacy named and no state list recorded
What the evidence says about this kind of treatment
The assessment above is about NuuVim. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A buyer weighing the oral against the injection on price alone.
- Wrong for
- A buyer who wants to pay one month at a time.
The evidence behind what NuuVim prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How NuuVim compares
| Seller | Who it suits | Go |
|---|---|---|
| EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | See EverSlim → |
 Science & Co | Patients who clarify the clinician, pharmacy and full plan terms before enrolling | See Science & Co → |
 Lean Meds | Readers willing to clarify the prescription and renewal details | See Lean Meds → |
More GLP-1 sellers by price reviews: HumeCare+Live VitalLttlLuvo HealthMEDGmOak
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Does the oral cost more than the injection?
- No. NuuVim prices both forms of each molecule identically — $133 for semaglutide and $199.67 for tirzepatide at the standard rate.
- Is $133 the price I will pay?
- It is the standard rate, billed $399 per three months. New GLP-1 users are shown a lower introductory tab, so confirm which figure applies before the first charge.
- How is it billed?
- In three-month blocks: $399 for semaglutide and $599 for tirzepatide, in either form.
- Is NuuVim expensive compared with other GLP-1 sellers by price?
- NuuVim publishes a starting figure of $133/mo. Across the 402 GLP-1 sellers by price we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts NuuVim below the median, toward the cheaper end. The other 178 GLP-1 sellers by price we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.